SABCS 2025 showcased several new strides in breast cancer research, which continues to be one of the most diagnosed malignancies globally, owing to the breadth of its subtypes: HR+, HER2+ and TNBC, all of which respond differently. In recent years, there have been several leaps in treatment options that have improved both outcomes and overall…
Theratechnologies announces positive preclinical data for its TH1902 peptide drug conjugate
Theratechnologies (NSDQ:THTX) announced that the peer-reviewed journal Cancer Science had published its preclinical research related to TH1902, a peptide linked to the chemotherapeutic agent docetaxel. The research tested the investigational drug as a sortilin-positive triple-negative breast cancer (TNBC) treatment. TNBC lacks the expression or amplification of targetable biomarker. The prognosis for this cancer subgroup tends…